Delivery Order SPE2DB24D2010-SPE2DB25FAAXS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $3,418.92. This is a firm fixed-price delivery order under a non-set-aside competitive procurement, with an ultimate completion date of August 19, 2025. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $20,876.59 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting the federal government's pharmaceutical supply chain. The contract will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $9,106.78 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $4,253.28. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a contract ceiling value of $14,438.26. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by August 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $16,140.92. This firm fixed-price delivery order is non-set-aside and reflects open competition, with an ultimate completion date of August 8, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAXSDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 22, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $18,961.13. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 25, 2025, and performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its DLA prime contract. The company has demonstrated capability to fulfill federal medical procurement requirements through open competition, with an extensive portfolio of delivery orders involving brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular delivery order for Dupixent, a specialty biologic medication, reflects the company's role in supplying advanced pharmaceutical therapies to support military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.0k | 8/22/25 |